Figitumumab (CP-751, 871, CP), a human anti-IGF-IR monoclonal antibody (mAb), is proved to have anti-proliferation and anti-tumorigenicity effects in cancer cells and xenografted mice, and it has been showed to be effective in combination with other cytotoxic agents to target many cancer types [12–14]. The gene discussed is IGF1R; the disease is cancer.